<DOC>
	<DOCNO>NCT01964872</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics , pharmacodynamic effect single oral dos multiple oral dos JNJ-38877618 administer 7 consecutive day healthy adult male participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-38877618 Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( individual assign study treatment chance ) , double-blind ( individual study personnel know identity study treatment ) , placebo ( inactive substance compare drug test whether drug real effect clinical trial ) -controlled study healthy adult male participant age 18 45 year ( single optional cohort old healthy male participant age 50 65 year may include ) . If optional cohort include , 144 participant may enrol . This study consist four part . Part 1 contain 3 subpart : Part 1a double-blind , placebo-controlled , single ascend dose design ( SAD ) liquid formulation ( Formulation A ) ; Part 1b open-label ( identity assign study drug know ) , single dose evaluation capsule formulation ( Formulation B ) ; Part 1c optional open-label , single dose evaluation capsule formulation ( Formulation C ) . Part 2 completion double-blind , placebo-controlled SAD formulation select base Parts 1a , 1b , 1c ( applicable ) . Part 3 double-blind , placebo-controlled , multiple ascend dose design ( MAD ) . Doses Part 3 determine base safety , tolerability , pharmacokinetics ( study body drug ) Parts 1 2 . Part 4 optional double-blind , placebo-controlled , single dose evaluation old healthy male participant . Serial pharmacokinetic pharmacodynamics ( study drug body ) sample collect safety monitor throughout study .</detailed_description>
	<criteria>Deemed healthy basis physical examination , medical history , laboratory test , vital sign , 12lead electrocardiogram within protocoldefined parameter perform screen Day 1 Must good exercise tolerance Agrees protocoldefined use effective contraception Body Mass Index 20 30 kg/m2 body weight less 65 kg Nonnicotine user 6 month prior screen Current history clinically significant medical illness History drug alcohol abuse within 5 year Routine consumption &gt; 450 mg caffeine per day Recent vaccination acute illness Blood donation major blood loss within 3 month prior study drug administration Use prescription overthecounter medication ( include paracetamol ) , herbal medication within 2 week dose study drug proton pump inhibitor within 6 week prior dose study drug Currently enrol investigational study , receive investigational drug vaccine , use invasive investigational medical device within 3 month plan first dose study drug Plans father child enrol study within 3 month last dose study drug Major surgery within 3 month study participation minor surgery within 6 week screen , 30 day last study drug administration Any condition , opinion investigator , participation would best interest participant could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>JNJ-38877618</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Safety</keyword>
	<keyword>Single-ascending dose</keyword>
	<keyword>Multiple-ascending dose</keyword>
</DOC>